Get started
Author

Miguel Antonio Escobar

Observed names: Escobar, Miguel A., M Escobar, M. A. ESCOBAR, M. A. Escobar, M. ESCOBAR, M. Escobar, M.A. ESCOBAR, M.A. Escobar, MIGUEL ESCOBAR, Miguel A Escobar, Miguel A. Escobar, Miguel A. Escobar MD, Miguel A. Escobar, MD, Miguel Escobar, Miguel A. Escobar, Miguel A. Escobar
Observed institutions: University of North Carolina at Chapel Hill, Mayo Clinic, University Medical Center Groningen, The University of Texas MD Anderson Cancer Center, Utrecht University, University of Michigan, Erasmus MC, University Medical Center Utrecht, Centro Internacional de Entrenamiento e Investigaciones Medicas, University of North Carolina Hospitals, Memorial Hermann–Texas Medical Center, Mayo Clinic in Florida, Amsterdam University Medical Centers, Ontwikkelingsmaatschappij Oost Nederland, UNC Lineberger Comprehensive Cancer Center, International Society on Thrombosis and Haemostasis, UConn Health, University of Amsterdam, Erasmus University Rotterdam, The University of Texas Health Science Center at Houston
ORCID: 0000-0002-2944-0240
Observed ORCID: 0000-0002-2944-0240
OpenAlex ID: A5087701839
Gene Therapy with Etranacogene Dezaparvovec for Hemophilia B
2023 · Steven W. Pipe, Frank W.G. Leebeek, et al. · New England Journal of Medicine · 367
PDF
BAX 335 hemophilia B gene therapy clinical trial results: potential impact of CpG sequences on gene expression
2020 · Barbara A. Konkle, Christopher E. Walsh, et al. · Blood · 189
Standardization of thromboelastography: a report from the TEG-ROTEM working group
2011 · M. CHITLUR, B. SORENSEN, et al. · Haemophilia · 151
PDF
Current Concepts of Hemostasis
2004 · Harold R. Roberts, Dougald M. Monroe, et al. · Anesthesiology · 127
PDF
Efficacy and safety of rVIII-SingleChain: results of a phase 1/3 multicenter clinical trial in severe hemophilia A
2016 · Johnny Mahlangu, Kazimierz Kuliczkowski, et al. · Blood · 90
Prophylaxis vs. on‐demand treatment with BAY 81‐8973, a full‐length plasma protein‐free recombinant factor VIII product: results from a randomized trial (LEOPOLD II)
2014 · K. Kavakli, K. Kavakli, et al. · Journal of Thrombosis and Haemostasis · 86
Recommendations on multidisciplinary management of elective surgery in people with haemophilia
2018 · M. A. Escobar, A. Brewer, et al. · Haemophilia · 81
PDF
A cross-sectional analysis of cardiovascular disease in the hemophilia population
2018 · Suman L. Sood, Dunlei Cheng, et al. · Blood Advances · 74
Antithrombotic Treatment in Patients With Hemophilia: an EHA-ISTH-EAHAD-ESO Clinical Practice Guidance
2023 · Roger E.G. Schutgens, Victor Jimenez-Yuste, et al. · HemaSphere · 68
In non‐severe hemophilia A the risk of inhibitor after intensive factor treatment is greater in older patients: a case–control study
2010 · C.L. KEMPTON, J.M. SOUCIE, et al. · Journal of Thrombosis and Haemostasis · 61
PDF
Antifactor Xa levels vs. activated partial thromboplastin time for monitoring unfractionated heparin. A pilot study
2016 · S. Samuel, T. A. Allison, et al. · Journal of Clinical Pharmacy and Therapeutics · 59
PDF
Major and Minor Classifications for Surgery in People With Hemophilia: A Literature Review
2017 · Luigi Piero Solimeno, Miguel A. Escobar, et al. · Clinical and Applied Thrombosis/Hemostasis · 55
PDF
American Cutaneous and Mucocutaneous Leishmaniasis (Tegumentary): A Diagnostic Challenge
1992 · Miguel A Escobar, Fernando Martinez, et al. · Tropical Doctor · 50
Health economics in haemophilia: a review from the clinician’s perspective
2010 · M. A. ESCOBAR · Haemophilia · 48
Haemoculture of Leishmania (Viannia) braziliensis from two cases of mucosal leishmaniasis: re-examination of haematogenous dissemination
1992 · Julia E. Martinez, Alba L. Arias, et al. · Transactions of the Royal Society of Tropical Medicine and Hygiene · 48
Recombinant von Willebrand factor prophylaxis in patients with severe von Willebrand disease: phase 3 study results
2022 · Frank W. G. Leebeek, Flora Peyvandi, et al. · Blood · 45
PDF
Integrated Hemophilia Patient Care via a National Network of Care Centers in the United States: A Model for Rare Coagulation Disorders
2021 · Leonard A Valentino, Judith R Baker, et al. · Journal of Blood Medicine · 43
PDF
Evaluation of the Use of Low-Dose 4-Factor Prothrombin Complex Concentrate in the Reversal of Direct Oral Anticoagulants in Bleeding Patients
2018 · Teresa A. Allison, Pei Jen Lin, et al. · Journal of Intensive Care Medicine · 43
Postoperative bleeding complications in patients with hemophilia undergoing major orthopedic surgery: A prospective multicenter observational study
2022 · Brendan Kleiboer, Marcus A. Layer, et al. · Journal of Thrombosis and Haemostasis · 41
Characterization of gp120 Hydrolysis by IgA Antibodies from Humans without HIV Infection
2007 · Stephanie Planque, Yukie Mitsuda, et al. · AIDS Research and Human Retroviruses · 41
Neutralization of genetically diverse HIV-1 strains by IgA antibodies to the gp120–CD4-binding site from long-term survivors of HIV infection
2010 · Stephanie Planque, Maria Salas, et al. · AIDS · 39
Clinical utility of viscoelastic testing (TEG and ROTEM analyzers) in the management of old and new therapies for hemophilia
2018 · Sarah Ramiz, Jan Hartmann, et al. · American Journal of Hematology · 38
PDF
Identification and characterization of novel mutations implicated in congenital fibrinogen disorders
2018 · Natalie Smith, Larissa Bornikova, et al. · Research and Practice in Thrombosis and Haemostasis · 38
PDF
Once‐weekly prophylaxis with glycoPEGylated recombinant factor VIII (N8‐GP) in severe haemophilia A: Safety and efficacy results from pathfinder 2 (randomized phase III trial)
2019 · Nicola Curry, Canan Albayrak, et al. · Haemophilia · 37
PDF
Characterization of the anti‐factor VIII immunoglobulin profile in patients with hemophilia A by use of a fluorescence‐based immunoassay
2014 · B. Boylan, A.S. Rice, et al. · Journal of Thrombosis and Haemostasis · 37
Works count: 199
Citation count: 2,989
H-index: 29
I10-index: 65
Year
Topic
Type